A cooperative effect of OTX015 and ibrutinib in ALK+ ALCL provides the rationale to explore BET inhibitors in T cell lymphoma as well as in auto-immune disorders. This evidence concerns the gene ALK and T-cell non-Hodgkin lymphoma.